Day: August 11, 2021

EDISON, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos”), a leading provider of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today announced financial results for the second quarter ended June 30, 2021 and updated guidance for full year 2021. Recent Business HighlightsBooked orders of $79.2 million year-to-date resulting in backlog of $95.6 million, as of August 11, 2021; current backlog delivers 100% coverage on 2021 $50 million revenue target $2 million in product shipped, as of August 11, 2021 Successfully completed UL certification on August 10, 2021 On July 7, 2021, Eos announced $100 million investment from Koch Strategic Platforms, a subsidiary of Koch Investments Group, to support the Company’s strategic growth initiativesEos Chief...

Completed a successful pre-IND meeting with the FDA for VRDN-001, a differentiated monoclonal antibody targeting IGF-1R for the treatment of Thyroid Eye DiseaseOn track to submit an IND filing with the FDA for VRDN-001 in the fourth quarter of 2021 and for key proof of concept clinical data in Thyroid Eye Disease patients in the second quarter of 2022 First VRDN-001 clinical trial data has potential to show rapid and substantial reduction in proptosis, the defining symptom of Thyroid Eye Disease Multiple abstracts accepted for upcoming presentation at the American Thyroid Association (ATA) Annual Meeting, highlighting preclinical data for Viridian’s differentiated IGF-1R antibodies Strengthened management team with appointments of Kristian Humer as Chief Financial Officer and Chief Business Officer and Deepa Rajagopalan, M.D. as SVP...

SAN FRANCISCO, Aug. 11, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD). The letter indicates the FDA will not approve the roxadustat NDA in its present form and has requested additional clinical study of roxadustat be conducted, prior to resubmission.   “We are deeply disappointed with this result, and this is an unfortunate day for patients suffering from anemia of CKD in the United States,” said Enrique Conterno, Chief Executive Officer, FibroGen. “Roxadustat is changing the lives of patients around the world, and we and our partner AstraZeneca will discuss next steps in the U.S.” Roxadustat is approved...

•  Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery •  FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal Surgery •  Brain Tumors Selected as the Initial Indication for Company’s OncoPLEX Intra-tumoral Cancer Therapy Program •  Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 11, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today provided a corporate update and reported financial results for the three and six months ended June 30, 2021. Recent Corporate Highlights:Recruitment...

Highlights:Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UKGuy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation“Everyone has a story: talking about mental health” podcast launched to eliminate stigma and open up dialogueConference call today at 1:00pm UK (8:00am ET)LONDON, Aug. 11, 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second...

HARTSVILLE, S.C., Aug. 11, 2021 (GLOBE NEWSWIRE) — Sonoco (NYSE: SON) today announced it will raise the price for all paperboard tubes and cores by a minimum of 8 percent, effective with shipments in the United States and Canada, on or after September 10, 2021. “Significant market tightness and additional inflationary cost pressures to our primary raw materials (uncoated recycled paperboard and adhesives) make this increase necessary,” said Doug Schwartz, Division Vice President and General Manager, North America Tubes and Cores. “Despite these market and supply chain challenges, we remain committed to maintaining the quality and service that our customers have become accustomed to when working with Sonoco.” Sonoco is the largest producer of paper-based tubes and cores in North America, which are used to serve the paper, plastic...

HOUSTON, Aug. 11, 2021 (GLOBE NEWSWIRE) — W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”) today announced that the Company will be participating in two upcoming investor conferences. The Company will participate in EnerCom, Inc.’s The Oil and Gas Conference in Denver, Colorado where Chairman and Chief Executive Officer Tracy W. Krohn is scheduled to make a presentation on Tuesday, August 17th at 4:00 pm Mountain Time. Senior management will also host one-on-one meetings with investors that day. The presentation will be webcast live and archived on W&T’s website, www.wtoffshore.com, in the “Investors” section. An updated investor slide deck will be posted in the “Investors” section of W&T’s website under “Presentations” on Tuesday morning, August 17th, 2021. The Company will also participate in the virtual...